{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:34:42Z","timestamp":1780450482336,"version":"3.54.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00115-019-0754-y","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T11:03:21Z","timestamp":1562151801000},"page":"817-823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nichtgehf\u00e4hige Patienten mit Duchenne-Muskeldystrophie","Non-ambulatory patients with Duchenne muscular dystrophy"],"prefix":"10.1007","volume":"90","author":[{"given":"Marina","family":"Flotats-Bastardas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ebrahimi-Fakhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Bernert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Schlachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Poryo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,3]]},"reference":[{"key":"754_CR1","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1542\/peds.110.S3.1304","volume":"110","author":"American Academy of Pediatrics","year":"2002","unstructured":"American Academy of Pediatrics, American Academy of Family Physicians, American College of Physicians-American Society of Internal Medicine (2002) A consensus statement on health care transitions for young adults with special health care needs. Pediatrics 110:1304\u20131306","journal-title":"Pediatrics"},{"key":"754_CR2","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1542\/peds.2018-0333J","volume":"142","author":"SD Apkon","year":"2018","unstructured":"Apkon\u00a0SD, Alman\u00a0B, Birnkrant\u00a0DJ et\u00a0al (2018) Orthopedic and surgical management of the patient with Duchenne muscular dystrophy. Pediatrics 142:S82\u2013S89","journal-title":"Pediatrics"},{"key":"754_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jpeds.2013.05.060","volume":"163","author":"BJ Barber","year":"2013","unstructured":"Barber\u00a0BJ, Andrews\u00a0JG, Lu\u00a0Z et\u00a0al (2013) Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J\u00a0Pediatr 163:1080\u20131084.e1081","journal-title":"J Pediatr"},{"key":"754_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1017\/S0012162206000351","volume":"48","author":"P Baxter","year":"2006","unstructured":"Baxter\u00a0P (2006) Treatment of the heart in Duchenne muscular dystrophy. Dev Med Child Neurol 48:163","journal-title":"Dev Med Child Neurol"},{"key":"754_CR5","first-page":"4","volume":"31","author":"L Beytia Mde","year":"2012","unstructured":"Beytia Mde\u00a0L, Vry\u00a0J, Kirschner\u00a0J (2012) Drug treatment of Duchenne muscular dystrophy: Available evidence and perspectives. Acta Myol 31:4\u20138","journal-title":"Acta Myol"},{"key":"754_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant\u00a0DJ, Bushby\u00a0K, Bann\u00a0CM et\u00a0al (2018) Diagnosis and management of Duchenne muscular dystrophy, Part 2: Respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17:347\u2013361","journal-title":"Lancet Neurol"},{"key":"754_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant\u00a0DJ, Bushby\u00a0K, Bann\u00a0CM et\u00a0al (2018) Diagnosis and management of Duchenne muscular dystrophy, Part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17:251\u2013267","journal-title":"Lancet Neurol"},{"key":"754_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant\u00a0DJ, Bushby\u00a0K, Bann\u00a0CM et\u00a0al (2018) Diagnosis and management of Duchenne muscular dystrophy, Part 3: Primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 17:445\u2013455","journal-title":"Lancet Neurol"},{"key":"754_CR9","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMra0800239","volume":"358","author":"E Braunwald","year":"2008","unstructured":"Braunwald\u00a0E (2008) Biomarkers in heart failure. N\u00a0Engl J Med 358:2148\u20132159","journal-title":"N Engl J Med"},{"key":"754_CR10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/mus.880040304","volume":"4","author":"MH Brooke","year":"1981","unstructured":"Brooke\u00a0MH, Griggs\u00a0RC, Mendell\u00a0JR et\u00a0al (1981) Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 4:186\u2013197","journal-title":"Muscle Nerve"},{"key":"754_CR11","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1542\/peds.2018-0333G","volume":"142","author":"D Brumbaugh","year":"2018","unstructured":"Brumbaugh\u00a0D, Watne\u00a0L, Gottrand\u00a0F et\u00a0al (2018) Nutritional and gastrointestinal management of the patient with Duchenne muscular dystrophy. Pediatrics 142:S53\u2013S61","journal-title":"Pediatrics"},{"key":"754_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.4155\/cli.11.113","volume":"1","author":"K Bushby","year":"2011","unstructured":"Bushby\u00a0K, Connor\u00a0E (2011) Clinical outcome measures for trials in Duchenne muscular dystrophy: Report from international working group meetings. Clin Investig (lond) 1:1217\u20131235","journal-title":"Clin Investig (lond)"},{"key":"754_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0960-8966(93)90060-W","volume":"3","author":"AA Chenard","year":"1993","unstructured":"Chenard\u00a0AA, Becane\u00a0HM, Tertrain\u00a0F et\u00a0al (1993) Ventricular arrhythmia in Duchenne muscular dystrophy: Prevalence, significance and prognosis. Neuromuscul Disord 3:201\u2013206","journal-title":"Neuromuscul Disord"},{"key":"754_CR14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/BPO.0000000000000396","volume":"36","author":"K Chua","year":"2016","unstructured":"Chua\u00a0K, Tan\u00a0CY, Chen\u00a0Z et al (2016) Long-term follow-up of pulmonary function and scoliosis in patients with Duchenne\u2019s muscular dystrophy and spinal muscular atrophy. J\u00a0Pediatr Orthop 36:63\u201369","journal-title":"J Pediatr Orthop"},{"key":"754_CR15","first-page":"261","volume":"5","author":"JR Cobb","year":"1948","unstructured":"Cobb\u00a0JR (1948) Outline for the study of scoliosis. Instr Course Lect 5:261\u2013275","journal-title":"Instr Course Lect"},{"key":"754_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.nmd.2017.02.006","volume":"27","author":"A D\u2019Amico","year":"2017","unstructured":"D\u2019Amico\u00a0A, Catteruccia\u00a0M, Baranello\u00a0G et\u00a0al (2017) Diagnosis of Duchenne muscular dystrophy in Italy in the last decade: Critical issues and areas for improvements. Neuromuscul Disord 27:447\u2013451","journal-title":"Neuromuscul Disord"},{"key":"754_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/CND.0b013e3181c5053b","volume":"11","author":"SE Davis","year":"2010","unstructured":"Davis\u00a0SE, Hynan\u00a0LS, Limbers\u00a0CA et\u00a0al (2010) The pedsQL in pediatric patients with Duchenne muscular dystrophy: Feasibility, reliability, and validity of the pediatric quality of life inventory neuromuscular module and generic core scales. J\u00a0Clin Neuromuscul Dis 11:97\u2013109","journal-title":"J Clin Neuromuscul Dis"},{"key":"754_CR18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.nmd.2007.03.002","volume":"17","author":"M Eagle","year":"2007","unstructured":"Eagle\u00a0M, Bourke\u00a0J, Bullock\u00a0R et\u00a0al (2007) Managing Duchenne muscular dystrophy\u2014The additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 17:470\u2013475","journal-title":"Neuromuscul Disord"},{"key":"754_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fped.2018.00316","volume":"6","author":"D Ebrahimi-Fakhari","year":"2018","unstructured":"Ebrahimi-Fakhari\u00a0D, Dillmann\u00a0U, Flotats-Bastardas\u00a0M et al (2018) Off-label use of ataluren in four non-ambulatory patients with nonsense mutation Duchenne muscular dystrophy: Effects on cardiac and pulmonary function and muscle strength. Front Pediatr 6:316","journal-title":"Front Pediatr"},{"key":"754_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","volume":"359","author":"AE Emery","year":"2002","unstructured":"Emery\u00a0AE (2002) The muscular dystrophies. Lancet 359:687\u2013695","journal-title":"Lancet"},{"key":"754_CR21","doi-asserted-by":"publisher","first-page":"e81302","DOI":"10.1371\/journal.pone.0081302","volume":"8","author":"RS Finkel","year":"2013","unstructured":"Finkel\u00a0RS, Flanigan\u00a0KM, Wong\u00a0B et al (2013) Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS ONE 8:e81302","journal-title":"PLoS ONE"},{"key":"754_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3233\/PRM-160358","volume":"9","author":"S Garg","year":"2016","unstructured":"Garg\u00a0S (2016) Management of scoliosis in patients with Duchenne muscular dystrophy and spinal muscular atrophy: A literature review. J\u00a0Pediatr Rehabil Med 9:23\u201329","journal-title":"J Pediatr Rehabil Med"},{"key":"754_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.nmd.2013.05.006","volume":"23","author":"N Goemans","year":"2013","unstructured":"Goemans\u00a0N, van den Hauwe\u00a0M, Wilson\u00a0R et al (2013) Ambulatory capacity and disease progression as measured by the 6\u2011minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscul Disord 23:618\u2013623","journal-title":"Neuromuscul Disord"},{"key":"754_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1469-7610.1997.tb01545.x","volume":"38","author":"R Goodman","year":"1997","unstructured":"Goodman\u00a0R (1997) The strengths and difficulties questionnaire: A\u00a0research note. J\u00a0Child Psychol Psychiatry 38:581\u2013586","journal-title":"J Child Psychol Psychiatry"},{"key":"754_CR25","volume-title":"A manual of diseases of the nervous system","author":"WR Gowers","year":"1892","unstructured":"Gowers\u00a0WR (1892) A manual of diseases of the nervous system. J. & A. Churchill, London"},{"key":"754_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1477-7525-5-31","volume":"5","author":"MA Grootenhuis","year":"2007","unstructured":"Grootenhuis\u00a0MA, de Boone\u00a0J, van der Kooi\u00a0AJ (2007) Living with muscular dystrophy: Health related quality of life consequences for children and adults. Health Qual Life Outcomes 5:31","journal-title":"Health Qual Life Outcomes"},{"key":"754_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejpn.2011.07.001","volume":"16","author":"V Humbertclaude","year":"2012","unstructured":"Humbertclaude\u00a0V, Hamroun\u00a0D, Bezzou\u00a0K et\u00a0al (2012) Motor and respiratory heterogeneity in Duchenne patients: Implication for clinical trials. Eur J Paediatr Neurol 16:149\u2013160","journal-title":"Eur J Paediatr Neurol"},{"key":"754_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JND-170280","volume":"4","author":"Z Koeks","year":"2017","unstructured":"Koeks\u00a0Z, Bladen\u00a0CL, Salgado\u00a0D et al (2017) Clinical outcomes in Duchenne muscular dystrophy: A study of 5345 patients from the TREAT-NMD DMD global database. J\u00a0Neuromuscul Dis 4:293\u2013306","journal-title":"J Neuromuscul Dis"},{"key":"754_CR29","first-page":"1243","volume-title":"Robbins and Cotran pathologic basis of disease","author":"V Kumar","year":"2015","unstructured":"Kumar\u00a0V, Abbas\u00a0AK, Fausto\u00a0N et\u00a0al (2015) In: Klatt\u00a0E, Kumar\u00a0V (Hrsg) Robbins and Cotran pathologic basis of disease. Elsevier Saunders, Philadelphia, S\u00a01243"},{"key":"754_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1026\/0012-1924\/a000153","volume":"61","author":"A Lohbeck","year":"2015","unstructured":"Lohbeck\u00a0A, Schulthei\u00df\u00a0J, Petermann\u00a0F et al (2015) Die deutsche Selbstbeurteilungsversion des strengths and difficulties questionnaire (SDQ-Deu-S). Diagnostica 61:222\u2013235","journal-title":"Diagnostica"},{"key":"754_CR31","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01418-2017","author":"A LoMauro","year":"2018","unstructured":"LoMauro\u00a0A, Romei\u00a0M, Gandossini\u00a0S et\u00a0al (2018) Evolution of respiratory function in Duchenne muscular dystrophy from childhood to adulthood. Eur Respir\u00a0J. https:\/\/doi.org\/10.1183\/13993003.01418-2017","journal-title":"Eur Respir J"},{"key":"754_CR32","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","volume":"24","author":"JK Mah","year":"2014","unstructured":"Mah\u00a0JK, Korngut\u00a0L, Dykeman\u00a0J et al (2014) A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 24:482\u2013491","journal-title":"Neuromuscul Disord"},{"key":"754_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12842","author":"S Mavrogeni","year":"2017","unstructured":"Mavrogeni\u00a0S, Pons\u00a0R, Nikas\u00a0I et\u00a0al (2017) Brain and heart magnetic resonance imaging\/spectroscopy in duchenne muscular dystrophy. Eur J Clin Invest. https:\/\/doi.org\/10.1111\/eci.12842","journal-title":"Eur J Clin Invest"},{"key":"754_CR34","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/dmcn.12213","volume":"55","author":"A Mayhew","year":"2013","unstructured":"Mayhew\u00a0A, Mazzone\u00a0ES, Eagle\u00a0M et\u00a0al (2013) Development of the performance of the upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 55:1038\u20131045","journal-title":"Dev Med Child Neurol"},{"key":"754_CR35","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.nmd.2010.06.014","volume":"20","author":"E Mazzone","year":"2010","unstructured":"Mazzone\u00a0E, Martinelli\u00a0D, Berardinelli\u00a0A et al (2010) North Star Ambulatory Assessment, 6\u2011minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 20:712\u2013716","journal-title":"Neuromuscul Disord"},{"key":"754_CR36","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.0b013e318225ab2e","volume":"77","author":"E Mazzone","year":"2011","unstructured":"Mazzone\u00a0E, Vasco\u00a0G, Sormani\u00a0MP et al (2011) Functional changes in Duchenne muscular dystrophy: A 12-month longitudinal cohort study. Neurology 77:250\u2013256","journal-title":"Neurology"},{"key":"754_CR37","volume-title":"Natural history of DMD\/ BMD: What is clinically meaningful?","author":"CM McDonald","year":"2013","unstructured":"McDonald\u00a0CM (2013) Natural history of DMD\/ BMD: What is clinically meaningful? (Vortrag, gehalten am 21. Juni 2013 in London)"},{"key":"754_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mus.23807","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald\u00a0CM, Henricson\u00a0EK, Abresch\u00a0RT et\u00a0al (2013) The cooperative international neuromuscular research group Duchenne natural history study\u2014A longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used. Muscle Nerve 48:32\u201354","journal-title":"Muscle Nerve"},{"key":"754_CR39","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mus.21544","volume":"41","author":"CM McDonald","year":"2010","unstructured":"McDonald\u00a0CM, Henricson\u00a0EK, Han\u00a0JJ et al (2010) The 6\u2011minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 41:500\u2013510","journal-title":"Muscle Nerve"},{"key":"754_CR40","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri\u00a0E, Signorovitch\u00a0JE, Swallow\u00a0E et al (2016) Categorizing natural history trajectories of ambulatory function measured by the 6\u2011minute walk distance in patients with Duchenne muscular dystrophy. Neuromuscul Disord 26:576\u2013583","journal-title":"Neuromuscul Disord"},{"key":"754_CR41","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jpeds.2014.07.006","volume":"165","author":"KT Mirski","year":"2014","unstructured":"Mirski\u00a0KT, Crawford\u00a0TO (2014) Motor and cognitive delay in Duchenne muscular dystrophy: Implication for early diagnosis. J\u00a0Pediatr 165:1008\u20131010","journal-title":"J Pediatr"},{"key":"754_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0167-5273(90)90082-G","volume":"26","author":"G Nigro","year":"1990","unstructured":"Nigro\u00a0G, Comi\u00a0LI, Politano\u00a0L et\u00a0al (1990) The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26:271\u2013277","journal-title":"Int J Cardiol"},{"key":"754_CR43","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00415-017-8406-2","volume":"264","author":"C Otto","year":"2017","unstructured":"Otto\u00a0C, Steffensen\u00a0BF, Hojberg\u00a0AL et al (2017) Predictors of health-related quality of life in boys with Duchenne muscular dystrophy from six European countries. J\u00a0Neurol 264:709\u2013723","journal-title":"J Neurol"},{"key":"754_CR44","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0735-1097(84)80186-2","volume":"3","author":"JK Perloff","year":"1984","unstructured":"Perloff\u00a0JK (1984) Cardiac rhythm and conduction in Duchenne\u2019s muscular dystrophy: A\u00a0prospective study of 20 patients. J\u00a0Am Coll Cardiol 3:1263\u20131268","journal-title":"J Am Coll Cardiol"},{"key":"754_CR45","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00415-006-0212-1","volume":"253","author":"S Pradhan","year":"2006","unstructured":"Pradhan\u00a0S, Ghosh\u00a0D, Srivastava\u00a0NK et\u00a0al (2006) Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. J\u00a0Neurol 253:1309\u20131316","journal-title":"J Neurol"},{"key":"754_CR46","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-2377-13-88","volume":"13","author":"S Schade van Westrum","year":"2013","unstructured":"Schade van Westrum\u00a0S, Dekker\u00a0L, de Haan\u00a0R et\u00a0al (2013) Brain natriuretic peptide is not predictive of dilated cardiomyopathy in Becker and Duchenne muscular dystrophy patients and carriers. BMC Neurol 13:88","journal-title":"BMC Neurol"},{"key":"754_CR47","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00115-018-0585-2","volume":"89","author":"U Schara","year":"2018","unstructured":"Schara\u00a0U, Fink\u00a0GR, von Moers\u00a0A (2018) Transition von der Neurop\u00e4diatrie zur Neurologie bei neuromuskul\u00e4ren Erkrankungen. Nervenarzt 89:1123\u20131130","journal-title":"Nervenarzt"},{"key":"754_CR48","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1542\/peds.2018-0333H","volume":"142","author":"DW Sheehan","year":"2018","unstructured":"Sheehan\u00a0DW, Birnkrant\u00a0DJ, Benditt\u00a0JO et\u00a0al (2018) Respiratory management of the patient with Duchenne muscular dystrophy. Pediatrics 142:S62\u2013S71","journal-title":"Pediatrics"},{"key":"754_CR49","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2106\/JBJS.M.00777","volume":"96","author":"KS Suk","year":"2014","unstructured":"Suk\u00a0KS, Lee\u00a0BH, Lee\u00a0HM et\u00a0al (2014) Functional outcomes in Duchenne muscular dystrophy scoliosis: comparison of the differences between surgical and nonsurgical treatment. J\u00a0Bone Joint Surg Am 96:409\u2013415","journal-title":"J Bone Joint Surg Am"},{"key":"754_CR50","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1542\/peds.2018-0333M","volume":"142","author":"CJ Trout","year":"2018","unstructured":"Trout\u00a0CJ, Case\u00a0LE, Clemens\u00a0PR et\u00a0al (2018) A transition toolkit for Duchenne muscular dystrophy. Pediatrics 142:S110\u2013S117","journal-title":"Pediatrics"},{"key":"754_CR51","doi-asserted-by":"publisher","first-page":"e1559","DOI":"10.1542\/peds.2012-0858","volume":"130","author":"K Uzark","year":"2012","unstructured":"Uzark\u00a0K, King\u00a0E, Cripe\u00a0L et al (2012) Health-related quality of life in children and adolescents with Duchenne muscular dystrophy. Pediatrics 130:e1559\u2013e1566","journal-title":"Pediatrics"},{"key":"754_CR52","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002620","author":"CR Villa","year":"2015","unstructured":"Villa\u00a0CR, Czosek\u00a0RJ, Ahmed\u00a0H et\u00a0al (2015) Ambulatory monitoring and arrhythmic outcomes in pediatric and adolescent patients with Duchenne muscular dystrophy. J\u00a0Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.115.002620","journal-title":"J Am Heart Assoc"},{"key":"754_CR53","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","volume":"35","author":"M Volpe","year":"2014","unstructured":"Volpe\u00a0M, Rubattu\u00a0S, Burnett\u00a0J Jr. (2014) Natriuretic peptides in cardiovascular diseases: Current use and perspectives. Eur Heart\u00a0J 35:419\u2013425","journal-title":"Eur Heart J"},{"issue":"S 01","key":"754_CR54","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1055\/s-0037-1602955","volume":"48","author":"C Werner","year":"2017","unstructured":"Werner\u00a0C, Kroger\u00a0H, Luo\u00a0X et al (2017) Lung function in ataluren-treated, nonambulatory patients with nonsense mutation Duchenne muscular dystrophy from a long-term extension trial. Neuropediatrics 48(S 01):S1\u2013S45. https:\/\/doi.org\/10.1055\/s-0037-1602955 (43rd Annual Meeting of the Society for Neuropediatrics, 27.\u201330.04.2017, Bad Nauheim, Germany)","journal-title":"Neuropediatrics"},{"key":"754_CR55","first-page":"5493","volume-title":"The metabolic and molecular basis of inherited disease","author":"RG Worton","year":"2001","unstructured":"Worton\u00a0RG et al (2001) The metabolic and molecular basis of inherited disease. McGraw-Hill, New York, S 5493\u20135523"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-0754-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-019-0754-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-0754-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T20:58:48Z","timestamp":1663880328000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-019-0754-y"}},"subtitle":["Empfehlungen zur Dokumentation des Krankheits- und Therapieverlaufs","Recommendations for monitoring disease progression and course of treatment"],"short-title":[],"issued":{"date-parts":[[2019,7,3]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s00115-019-0754-y","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,3]]},"assertion":[{"value":"3 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Flotats-Bastardas: Teilnahme an einem Advisory Board Meeting der Firma PTC Therapeutics. D.\u00a0Ebrahimi-Fakhari: Teilnahme an einem Advisory Board Meeting der Fa. PTC Therapeutics. Finanzielle Unterst\u00fctzung der Studie ESPED-TSC durch Fa. Novartis. G.\u00a0Bernert: Teilnahme an Advisory Board Meetinsg von PTC Therapeutics und Santhera Pharmaceuticals; Beratertatigkeit f\u00fcr PTC Therapeutics. A.\u00a0Ziegler: Teilnahme an einem Advisory Board Meeting von PTC Therapeutics. K.\u00a0Schlachter: Teilnahme an einem Advisory Board Meeting von PTC Therapeutics. A.\u00a0Hahn: Teilnahme an einem Advisory Board Meeting von PTC Therapeutics sowie Honorare und Reisesponsering f\u00fcr Vortr\u00e4ge von den Firmen Sanofi-Genzyme, Actelion, Amicus, Sarepta, Biogen, Shire, Avexis und Biomarin. S.\u00a0Meyer: Teilnahme an Advisory Board Meetings von PTC Therapeutics. Finanzielle Unterst\u00fctzung der Studie ESPED-TSC durch Firma Novartis; Reisesponsering f\u00fcr Vortr\u00e4ge von den Firmen Actelion, Shire und Nestl\u00e9. Finanzielle F\u00f6rderung durch DFG im Rahmen der Studie NeoVitaA (ME 3827\/1-1). M.\u00a0Poryo gibt an, dass kein Interessenkonflikt besteht. PTC Therapeutics hatte keinerlei Einfluss auf den Inhalt dieses Konsensus-Statements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}